ClinicalTrials.gg
CompletedNCT02501902Updated Apr 6, 2021Results posted

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

A Phase 1 interventional study of Palbociclib and Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Pfizer. Completed at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-06.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be enrolled in the overall study.

Read the detailed description

The study has 2 parts:

  • Part A (Dose-Escalation Cohorts): Consecutive cohorts of patients will receive escalating doses of oral palbociclib in combination with intravenous nab-P in 28-day cycles, in order to estimate the MTD(s) of the combination. The starting doses will be 75 mg palbociclib, and 100 mg/m2 nab-P. The observation period for dose-limiting toxicities (DLTs) will be from Day 1 to Day 28. Pharmacokinetic (PK) and pharmacodynamic (PD) properties of palbociclib and nab-P will also be assessed. Up to approximately 30 patients will be enrolled. The criteria for dose escalation will be based on a modified toxicity probability interval (mTPI) method.
  • Part B [MTD Expansion Cohort(s)]: When the MTD(s) of palbociclib plus nab-P has been estimated with confidence, enrollment will proceed into 1 or 2 MTD expansion cohort(s) of up to 20 patients each at the MTD(s). The objective of the MTD expansion cohort(s) will be to provide additional information on safety, tolerability, biomarkers, PD activity, and PK/PD relationship for the combination regimen in order to determine the RP2D. The MTD expansion cohort(s) will only enroll patients who have not received previous treatment for their metastatic disease in order to evaluate preliminary activity of the combination in the target patient population.

All patients (in Part A and B) will receive nab-P intravenously once weekly for 3 weeks out of each 28-day cycle. Palbociclib oral dosing will be once daily on Days 1-21 of each 28-day cycle. To allow for PK evaluation of nab-P administered alone, nab-P will be administered on Day -2 for Cycle 1 only. Subsequent cycles will administer both nab-P and palbociclib on Day 1. Alternate dosing schedules for palbociclib may be explored based on emerging PK, PD, and safety data.

Patients will be treated as long as they are clinically benefiting from investigational product without unacceptable toxicity, objective disease progression, or withdrawal of consent. A modified visit schedule will be implemented for patients who are on investigational product for more than 2 years.

02

Conditions studied

  • Metastatic Pancreatic Ductal Adenocarcinoma

Keywords

  • Ibrance, palbociclib, Abraxane, nab-paclitaxel, pancreas,
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically-confirmed pancreatic ductal adenocarcinoma.
  • Availability of a tumor tissue specimen. If no archived tumor tissue is available, then a de novo is required for patient participation.
  • Performance Status 70 or greater.
  • Adequate Bone Marrow, Renal, and Liver Function.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a CDK 4/6 inhibitor.
  • Prior treatment with nab-P for the treatment of disease.
  • Patients with known , carcinomatous meningitis, or as indicated by clinical symptoms, cerebral edema, and/or progressive growth.
  • Diagnosis of any other within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
  • >480 msec, or family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.
  • Uncontrolled electrolyte disorders.
  • Cardiac or pulmonary disorders within 6 months of enrollment.
  • Known infection.
  • History of interstitial lung disease or pneumonitis.
  • Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-P.
  • Difficulty swallowing capsules or requirement for a feeding tube.
  • Previous high-dose chemotherapy requiring stem cell rescue.
  • Pregnant female patients; breastfeeding female patients; male patients with partners currently pregnant.
  • Active inflammatory or other gastrointestinal disease,
  • Active bleeding disorder in the past 6 months.
  • Patients treated within the last 7 days prior to the start of IP with strong/moderate inhibitors, strong/moderate CYP3A4 inducers, CYP2C8 inhibitors, strong/moderate CYP2C8 inducers, or drugs that are known to prolong the QT interval.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Palbociclib + Nab-Paclitaxel

    Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.

    Drug: Palbociclib · Drug: Nab-Paclitaxel

Interventions

  • Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.

    Also known as: Ibrance

  • Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.

    Also known as: Abraxane

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities

    Adverse events (AEs) considered as dose limiting toxicities (DLTs) included: hematologic: Grade 4 neutropenia lasting \>4 days; Febrile neutropenia (defined as neutropenia Grade\>=3 \[absolute neutrophil count {ANC}\<1000 cells/cubic millimeter {mm\^3}\] and a body temperature \>=38.5 \[degrees centigrade\]℃) requiring antibiotic or antifungal treatment; any Grade 4 thrombocytopenia (\<25000/mm\^3 or 25.0\*10\^9/\[liter\]L). Non-hematologic: Grade \>=3 toxicities, except those that had not been maximally treated (eg, nausea, vomiting, diarrhea). Any AE that caused a palbociclib treatment interruption of greater than 7 consecutive days or caused any combination of interruption/reduction for \>=14 days. Any AE that caused omission or reduction of at least 2 of the 3 weekly doses of nab-P.

    Time frame: From Day 1 until pre-dose Cycle 2 Day 1

Secondary outcomes

  1. Number of Participants With Adverse Events

    An AE was any untoward medical occurrence in a clinical investigation patient administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An serious AE (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of investigational product. Disease progression was not considered a treatment emergent AE unless the participant died of disease prior to 28 days after discontinuation of treatment. Treatment emergent AEs with cause possibly, probably or definitely related to treatment, as judged by the investigator, were defined as treatment-related AEs. AEs were graded by investigator according to CTCAE v4.03.

    Time frame: From the signing of informed consent up to 56 days after the last administration of the investigational product, or 365 days from the first dose of investigational product, whichever is later

  2. Number of Participants With Laboratory Abnormalities

    The number of participants with following laboratory abnormalities meeting any of the Grades 1 to 4 classified according to NCI CTCAE v4.0 were summarized: hematology (anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils, platelets and white blood cells) and chemistry laboratory tests (alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, creatinine, hypercalcemia, hyperglocemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, lipase).

    Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).

  3. Number of Participants With Vital Signs Data Meeting Pre-specified Criteria

    Vital signs evaluation included sitting diastolic blood pressure (DBP), systolic blood pressure (SBP), and pulse rate. Suggest text: Vital signs categorical summary included: 1)SBP\>150mmHg or DBP\>100mmHg; 2)SBP\>200mmHg or DBP\>110mmHg; 3)SBP increase \>=20 and \<40mmHg; 4)SBP increase \>=40 and \<60mmHg; 5)SBP increase\>=60mmHg; 6)DBP increase \>=10 and \<20mmHg; 7)DBP increase \>=20 and \<30mmHg; 8)DBP increase \>=30mmHg; 9)pulse rate\>120bpm; 10)pulse rate\<50bpm.

    Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).

  4. Number of Participants With 20% Maximum Reduction From Baseline in Ca19-9

    Carbohydrate antigen 19-9 (Ca19-9) is a clinical pharmacodynamic (PD) marker associated with metastatic pancreatic ductal adenocarcinoma (mPDAC).

    Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).

  5. Number of Participants With 50% Maximum Reduction From Baseline in Ca19-9

    Ca19-9 is a clinical PD marker associated with metastatic mPDAC.

    Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).

  6. Number of Participants With 70% Maximum Reduction From Baseline in Ca19-9

    Ca19-9 is a clinical PD marker associated with metastatic mPDAC.

    Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).

  7. Number of Participants With 90% Maximum Reduction From Baseline in Ca19-9

    Ca19-9 is a clinical PD marker associated with metastatic mPDAC.

    Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).

  8. Objective Response Rate

    Percentage of participants who achieved objective response (OR) based on investigator assessment is presented. OR is defined as a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Objective response rate (ORR) was defined as the percentage of participants with a best overall response of CR or PR relative to all anti-tumor evaluable participants.

    Time frame: From screening to 365 days from the last dose of investigational product

  9. Duration of Response

    The duration of response was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.

    Time frame: From screening to 365 days from the last dose of investigational product

  10. Progression Free Survival

    The progression free survival (PFS) was defined as the time from the date of first dose to the date of the first documentation of objective tumor progression as per RECIST v1.1 or death due to any cause in the absence of documented progression disease, whichever occurred first.

    Time frame: From screening to 365 days from the last dose of investigational product

  11. Six-month Progression-free Survival Rate (6m-PFSR)

    6m-PFS was defined as PFS status (progression free and alive, or not) at Month 6. It was summarized as a product limit estimator based on the Kaplan-Meier method to account for censored events.

    Time frame: From screening to 6 months after first dose of investigational product

  12. Overall Survival (OS)

    OS was defined as the time from the date of first dose to the date of death due to any cause. Following the end of treatment visit, survival status was collected in all participants every month until 12 months (365 days) had elapsed from the last dose of investigational product.

    Time frame: From screening to 365 days from the last dose of investigational product

  13. Number of Participants With Positive p16

    p16 is a tumor suppressor protein which plays an important role in cell cycle regulation. The analysis of biomarker p16 expression might aid in the identification of patient subpopulations most likely to benefit from treatment. The results from p16 expression testing by immunohistochemistry (IHC) was used for sensitivity analyses. (a) and (b) :p16 cutoff utilizing the optimal cut point identified by the ORC analysis for the OS (a) or PFS (b) and the p16 positive tumor cells.

    Time frame: From Day-2 to up to 63 days from last dose of investigational product

  14. Retinoblastoma Protein (Rb) Percent Positive Cell (Nuclear Staining)

    Rb is a tumor suppressor protein that is dysfunctional in several major cancers. The results from Rb expression testing by IHC was used for sensitivity analyses.

    Time frame: From Day-2 to up to 63 days from last dose of investigational product

  15. Rb H-score Nuclear Staining

    Rb is a tumor suppressor protein that is dysfunctional in several major cancers. The results from Rb expression testing by IHC was used for sensitivity analyses. The H-score is a method of assessing the extent of nuclear immunoreactivity, applicable to steroid receptors. The score is obtained by the formula: 3\*percentage of strongly staining nuclei + 2\*percentage of moderately staining nuclei + percentage of weakly staining nuclei, giving the range of 0 to 300

    Time frame: From Day-2 to up to 63 days from last dose of investigational product

  16. Palbociclib Multiple Dose Maximum Plasma Concentration (Cmax)

    The palbociclib multiple dose maximum plasma concentration(Cmax) was observed directly from data.

    Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.

  17. Palbociclib Multiple Dose Time for Cmax (Tmax)

    The palbociclib multiple dose time for Cmax (Tmax) was observed directly from data.

    Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.

  18. Palbociclib Area Under the Plasma Concentration-time Curve for Dosing Interval τ (AUCτ)

    The palbociclib area under the plasma concentration-time curve for dosing interval τ (AUCτ) was observed directly from data.

    Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.

  19. Palbociclib Multiple Dose Trough Plasma Concentration(Ctrough)

    The palbociclib multiple dose trough plasma concentration (Ctrough) was observed directly from data.

    Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.

  20. Palbociclib Multiple Dose Apparent Clearance (CL/F)

    The palbociclib multiple dose apparent clearance (CL/F) was observed directly from data.

    Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.

  21. Nab-P Cmax

    The nab-P Cmax on Cycle 1 Day -1 and Day 13 were observed directly from data.

    Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.

  22. Nab-P Tmax

    The nab-P Tmax on Day -1 and Day 13 were observed directly from data.

    Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.

  23. Nab-P Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUClast)

    The nab-P area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast) on Day -1 and Day 13 were observed directly from data.

    Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.

  24. Nab-P Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)

    The nab-P area under the plasma concentration-time curve from time 0 extrapolated to infinite time (AUCinf) on Day -1 and Day 13 observed directly from data.

    Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.

  25. Nab-P Terminal Plasma Elimination Half-life (t1/2)

    The nab-P t1/2 on Day -1 and Day 13 were observed directly from data.

    Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.

  26. Nab-P Clearance (CL)

    The nab-P clearance on Day -1 and Day 13 were observed directly from data.

    Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.

  27. Nab-P Volume of Distribution (Vz)

    The nab-P on Day -1 and Day 13 were observed directly from data.

    Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.

07

Results

Posted Apr 6, 2021
Limitations and caveats
The rationale for the study was supported on theoretical and preclinical grounds. However, based on emerging clinical data, the combination of palbociclib and nab-P was not to be further developed.

Participant flow

Participant flow — Overall Study
MilestoneDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100mg/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100 mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2
Started374111111920
Completed00000000
Not completed374111111920
Withdrew: Subject refused further follow-up00000001
Withdrew: Study terminated by sponsor03011024
Withdrew: Death344101011715

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities

Adverse events (AEs) considered as dose limiting toxicities (DLTs) included: hematologic: Grade 4 neutropenia lasting \>4 days; Febrile neutropenia (defined as neutropenia Grade\>=3 \[absolute neutrophil count {ANC}\<1000 cells/cubic millimeter {mm\^3}\] and a body temperature \>=38.5 \[degrees centigrade\]℃) requiring antibiotic or antifungal treatment; any Grade 4 thrombocytopenia (\<25000/mm\^3 or 25.0\*10\^9/\[liter\]L). Non-hematologic: Grade \>=3 toxicities, except those that had not been maximally treated (eg, nausea, vomiting, diarrhea). Any AE that caused a palbociclib treatment interruption of greater than 7 consecutive days or caused any combination of interruption/reduction for \>=14 days. Any AE that caused omission or reduction of at least 2 of the 3 weekly doses of nab-P.

Time frame:
From Day 1 until pre-dose Cycle 2 Day 1
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities
ParticipantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2
Number of Participants With Dose Limiting Toxicities0100111
SecondaryNumber of Participants With Adverse Events

An AE was any untoward medical occurrence in a clinical investigation patient administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An serious AE (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of investigational product. Disease progression was not considered a treatment emergent AE unless the participant died of disease prior to 28 days after discontinuation of treatment. Treatment emergent AEs with cause possibly, probably or definitely related to treatment, as judged by the investigator, were defined as treatment-related AEs. AEs were graded by investigator according to CTCAE v4.03.

Time frame:
From the signing of informed consent up to 56 days after the last administration of the investigational product, or 365 days from the first dose of investigational product, whichever is later
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
All causality treatment-emergent AEs37411111192027
Treatment-related treatment-emergent AEs37410111192027
All causality SAEs24346921215
Treatment-related SAES001024166
All causality Grade 3 or 4 AEs3639111052027
Treatment-related Grade 3 or 4 AEs252811742027
All causality Grade 5 AEs011135012
Treatment-related Grade 5 AEs000010000
SecondaryNumber of Participants With Laboratory Abnormalities

The number of participants with following laboratory abnormalities meeting any of the Grades 1 to 4 classified according to NCI CTCAE v4.0 were summarized: hematology (anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils, platelets and white blood cells) and chemistry laboratory tests (alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, creatinine, hypercalcemia, hyperglocemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, lipase).

Time frame:
From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Anemia37411111182027
Hemoglobin increased000000011
Lymphocyte count increased010100000
Lymphopenia3729101172027
Neutrophils (absolute)3721010982027
Platelets24088511015
White blood cells3731010982027
Alanine aminotransferase (ALT)24134451115
Alkaline phosphatase26398861520
Amylase001110112
Aspartate aminotransferase (AST)2315656813
Bilirubin (total)020102044
Creatinine37310111091825
Hypercalcemia001010012
Hyperglycemia373971071623
Hyperkalemia002142369
Hypermagnesemia000000022
Hypernatremia010001222
Hypoalbuminemia22355741013
Hypocalcemia2225555912
Hypoglycemia111130036
Hypokalemia220011056
Hypomagnesemia102131036
Hyponatremia323633268
Hypophosphatemia011403266
Liapase111222256
SecondaryNumber of Participants With Vital Signs Data Meeting Pre-specified Criteria

Vital signs evaluation included sitting diastolic blood pressure (DBP), systolic blood pressure (SBP), and pulse rate. Suggest text: Vital signs categorical summary included: 1)SBP\>150mmHg or DBP\>100mmHg; 2)SBP\>200mmHg or DBP\>110mmHg; 3)SBP increase \>=20 and \<40mmHg; 4)SBP increase \>=40 and \<60mmHg; 5)SBP increase\>=60mmHg; 6)DBP increase \>=10 and \<20mmHg; 7)DBP increase \>=20 and \<30mmHg; 8)DBP increase \>=30mmHg; 9)pulse rate\>120bpm; 10)pulse rate\<50bpm.

Time frame:
From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria
ParticipantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Maximum on-study SBP>150 or DBP>100110222145
Maximum on-study SBP >200 or DBP>110000000000
Maximum increase from Baseline SBP>=20 and SBP<40000502144
Maximum increase from Baseline SBP>=40 and SBP<60000030013
Maximum increase from Baseline SBP>=60000000000
Maximum increase from Baseline DBP>=10 and DPB<20001351469
Maximum increase from Baseline DBP>= 20 and DBP<30000000111
Maximum increase from Baseline DBP >=30010110001
Maximum on-study pulse rate (bpm) >120000000000
Maximum on-study pulse rate (bpm) <50000000000
SecondaryNumber of Participants With 20% Maximum Reduction From Baseline in Ca19-9

Carbohydrate antigen 19-9 (Ca19-9) is a clinical pharmacodynamic (PD) marker associated with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Time frame:
From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Reported as:
Count of participants · Participants
Number of Participants With 20% Maximum Reduction From Baseline in Ca19-9
ParticipantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Number of Participants With 20% Maximum Reduction From Baseline in Ca19-935076531015
SecondaryNumber of Participants With 50% Maximum Reduction From Baseline in Ca19-9

Ca19-9 is a clinical PD marker associated with metastatic mPDAC.

Time frame:
From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Reported as:
Count of participants · Participants
Number of Participants With 50% Maximum Reduction From Baseline in Ca19-9
ParticipantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Number of Participants With 50% Maximum Reduction From Baseline in Ca19-91405642510
SecondaryNumber of Participants With 70% Maximum Reduction From Baseline in Ca19-9

Ca19-9 is a clinical PD marker associated with metastatic mPDAC.

Time frame:
From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Reported as:
Count of participants · Participants
Number of Participants With 70% Maximum Reduction From Baseline in Ca19-9
ParticipantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Number of Participants With 70% Maximum Reduction From Baseline in Ca19-9010341148
SecondaryNumber of Participants With 90% Maximum Reduction From Baseline in Ca19-9

Ca19-9 is a clinical PD marker associated with metastatic mPDAC.

Time frame:
From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Reported as:
Count of participants · Participants
Number of Participants With 90% Maximum Reduction From Baseline in Ca19-9
ParticipantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Number of Participants With 90% Maximum Reduction From Baseline in Ca19-9000010012
SecondaryObjective Response Rate

Percentage of participants who achieved objective response (OR) based on investigator assessment is presented. OR is defined as a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Objective response rate (ORR) was defined as the percentage of participants with a best overall response of CR or PR relative to all anti-tumor evaluable participants.

Time frame:
From screening to 365 days from the last dose of investigational product
Reported as:
Number · Percentage of participants
Objective Response Rate
Percentage of participantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Objective Response Rate————28.6 (3.7 to 71.0)——6.3 (0.2 to 30.2)13.0 (2.8 to 33.6)
SecondaryDuration of Response

The duration of response was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.

Time frame:
From screening to 365 days from the last dose of investigational product
Reported as:
Median · Months
Duration of Response
MonthsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Duration of Response————NA (3.8 to NA)——7.4 (NA to NA)7.4 (3.8 to NA)
SecondaryProgression Free Survival

The progression free survival (PFS) was defined as the time from the date of first dose to the date of the first documentation of objective tumor progression as per RECIST v1.1 or death due to any cause in the absence of documented progression disease, whichever occurred first.

Time frame:
From screening to 365 days from the last dose of investigational product
Reported as:
Median · Months
Progression Free Survival
MonthsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Progression Free Survival9.1 (3.7 to 9.1)9.5 (1.8 to NA)1.7 (1.4 to 1.9)3.5 (1.7 to 7.2)5.5 (0.8 to 14.5)5.3 (1.6 to 6.9)1.8 (1.5 to 8.6)3.8 (2.4 to 9.7)5.3 (3.5 to 9.7)
SecondarySix-month Progression-free Survival Rate (6m-PFSR)

6m-PFS was defined as PFS status (progression free and alive, or not) at Month 6. It was summarized as a product limit estimator based on the Kaplan-Meier method to account for censored events.

Time frame:
From screening to 6 months after first dose of investigational product
Reported as:
Number · Percentage of participants
Six-month Progression-free Survival Rate (6m-PFSR)
Percentage of participantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Six-month Progression-free Survival Rate (6m-PFSR)66.7 (5.4 to 94.5)66.7 (19.5 to 90.4)NA (NA to NA)30.0 (7.1 to 57.8)36.4 (11.2 to 62.7)27.3 (6.5 to 53.9)25.0 (3.7 to 55.8)36.2 (13.4 to 59.9)36.5 (17.0 to 56.3)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of first dose to the date of death due to any cause. Following the end of treatment visit, survival status was collected in all participants every month until 12 months (365 days) had elapsed from the last dose of investigational product.

Time frame:
From screening to 365 days from the last dose of investigational product
Reported as:
Median · Months
Overall Survival (OS)
MonthsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Overall Survival (OS)9.8 (8.8 to 16.3)23.4 (5.6 to NA)3.3 (2.1 to 7.7)7.2 (4.0 to 15.3)9.9 (0.8 to 14.8)5.3 (2.4 to 11.7)7.2 (4.0 to NA)11.4 (4.5 to 14.9)12.1 (6.4 to 14.8)
SecondaryNumber of Participants With Positive p16

p16 is a tumor suppressor protein which plays an important role in cell cycle regulation. The analysis of biomarker p16 expression might aid in the identification of patient subpopulations most likely to benefit from treatment. The results from p16 expression testing by immunohistochemistry (IHC) was used for sensitivity analyses. (a) and (b) :p16 cutoff utilizing the optimal cut point identified by the ORC analysis for the OS (a) or PFS (b) and the p16 positive tumor cells.

Time frame:
From Day-2 to up to 63 days from last dose of investigational product
Reported as:
Count of participants · Participants
Number of Participants With Positive p16
ParticipantsDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
p16(a)12057631015
p16(b)1104641913
SecondaryRetinoblastoma Protein (Rb) Percent Positive Cell (Nuclear Staining)

Rb is a tumor suppressor protein that is dysfunctional in several major cancers. The results from Rb expression testing by IHC was used for sensitivity analyses.

Time frame:
From Day-2 to up to 63 days from last dose of investigational product
Reported as:
Mean · Percentage of positive cell
Retinoblastoma Protein (Rb) Percent Positive Cell (Nuclear Staining)
Percentage of positive cellDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Retinoblastoma Protein (Rb) Percent Positive Cell (Nuclear Staining)88.3 ± 7.6480.0 ± 29.7968.8 ± 23.2391.1 ± 10.2490.5 ± 18.7792.5 ± 8.2582.2 ± 32.7092.4 ± 19.1091.7 ± 19.54
SecondaryRb H-score Nuclear Staining

Rb is a tumor suppressor protein that is dysfunctional in several major cancers. The results from Rb expression testing by IHC was used for sensitivity analyses. The H-score is a method of assessing the extent of nuclear immunoreactivity, applicable to steroid receptors. The score is obtained by the formula: 3\*percentage of strongly staining nuclei + 2\*percentage of moderately staining nuclei + percentage of weakly staining nuclei, giving the range of 0 to 300

Time frame:
From Day-2 to up to 63 days from last dose of investigational product
Reported as:
Mean · Scores on a scale
Rb H-score Nuclear Staining
Scores on a scaleDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Rb H-score Nuclear Staining158.3 ± 34.03154.0 ± 65.9108.8 ± 43.28166.7 ± 32.88176.0 ± 47.31172.5 ± 32.17145.6 ± 70.51187.9 ± 52.37185.4 ± 51.63
SecondaryPalbociclib Multiple Dose Maximum Plasma Concentration (Cmax)

The palbociclib multiple dose maximum plasma concentration(Cmax) was observed directly from data.

Time frame:
Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Reported as:
Geometric mean · nanogram per milli liter (ng/mL)
Palbociclib Multiple Dose Maximum Plasma Concentration (Cmax)
nanogram per milli liter (ng/mL)DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2
Palbociclib Multiple Dose Maximum Plasma Concentration (Cmax)NA ± NA90.68 ± 2457.30 ± 5698.79 ± 4664.55 ± 2348.05 ± 5453.65 ± 2570.14 ± 4390.44 ± 39
SecondaryPalbociclib Multiple Dose Time for Cmax (Tmax)

The palbociclib multiple dose time for Cmax (Tmax) was observed directly from data.

Time frame:
Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Reported as:
Median · hour(hr)
Palbociclib Multiple Dose Time for Cmax (Tmax)
hour(hr)DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Palbociclib Multiple Dose Time for Cmax (Tmax)4.93 (4.20 to 5.65)5.00 (4.00 to 7.92)3.90 (3.00 to 24.0)5.83 (4.05 to 25.0)4.50 (3.88 to 6.25)5.00 (1.83 to 7.17)6.01 (0 to 8.00)4.17 (0.600 to 7.98)5.05 (0 to 25.0)
SecondaryPalbociclib Area Under the Plasma Concentration-time Curve for Dosing Interval τ (AUCτ)

The palbociclib area under the plasma concentration-time curve for dosing interval τ (AUCτ) was observed directly from data.

Time frame:
Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Reported as:
Geometric mean · nanogram*hour per milli liter (ng.hr/mL)
Palbociclib Area Under the Plasma Concentration-time Curve for Dosing Interval τ (AUCτ)
nanogram*hour per milli liter (ng.hr/mL)DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Palbociclib Area Under the Plasma Concentration-time Curve for Dosing Interval τ (AUCτ)NA ± NA1497 ± 18897.4 ± 361867 ± 401169 ± 21767.9 ± 42967.7 ± 261251 ± 381569 ± 34
SecondaryPalbociclib Multiple Dose Trough Plasma Concentration(Ctrough)

The palbociclib multiple dose trough plasma concentration (Ctrough) was observed directly from data.

Time frame:
Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Reported as:
Geometric mean · ng/mL
Palbociclib Multiple Dose Trough Plasma Concentration(Ctrough)
ng/mLDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Palbociclib Multiple Dose Trough Plasma Concentration(Ctrough)NA ± NA43.42 ± 3426.84 ± 1971.82 ± 4241.92 ± 1122.34 ± 3730.66 ± 3434.89 ± 3448.51 ± 38
SecondaryPalbociclib Multiple Dose Apparent Clearance (CL/F)

The palbociclib multiple dose apparent clearance (CL/F) was observed directly from data.

Time frame:
Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Reported as:
Geometric mean · liter per hour (L/hr)
Palbociclib Multiple Dose Apparent Clearance (CL/F)
liter per hour (L/hr)DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Palbociclib Multiple Dose Apparent Clearance (CL/F)NA ± NA66.67 ± 1883.63 ± 3664.52 ± 4085.42 ± 2197.67 ± 4277.62 ± 2679.95 ± 3879.35 ± 34
SecondaryNab-P Cmax

The nab-P Cmax on Cycle 1 Day -1 and Day 13 were observed directly from data.

Time frame:
Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Reported as:
Geometric mean · ng/mL
Nab-P Cmax
ng/mLDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Day -11208 ± 2501595 ± 611869 ± 472733 ± 1273396 ± 1173271 ± 1131851 ± 1963054 ± 1292827 ± 121
Day 13NA ± NA1532 ± 1462316 ± 561265 ± 2193073 ± 572821 ± 931266 ± 1673448 ± 732487 ± 111
SecondaryNab-P Tmax

The nab-P Tmax on Day -1 and Day 13 were observed directly from data.

Time frame:
Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Reported as:
Median · hr
Nab-P Tmax
hrDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Day -10.500 (0.500 to 1.00)1.00 (0.500 to 1.13)1.00 (0.517 to 1.00)0.567 (0.483 to 1.00)0.600 (0.483 to 1.00)0.500 (0.450 to 1.03)0.775 (0.500 to 1.00)0.500 (0.000 to 1.17)0.517 (0.000 to 1.17)
Day 130.592 (0.583 to 0.600)0.583 (0.500 to 1.20)0.500 (0.500 to 1.00)1.00 (0.500 to 1.05)0.517 (0.467 to 1.00)0.500 (0.450 to 1.17)0.575 (0.500 to 1.03)0.533 (0.467 to 1.50)0.542 (0.450 to 1.50)
SecondaryNab-P Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUClast)

The nab-P area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast) on Day -1 and Day 13 were observed directly from data.

Time frame:
Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Reported as:
Geometric mean · ng.hr/mL
Nab-P Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUClast)
ng.hr/mLDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Day -12071 ± 1273501 ± 483489 ± 334291 ± 704895 ± 544472 ± 592632 ± 1463942 ± 604211 ± 70
Day 13NA ± NA2592 ± 704096 ± 642894 ± 1334095 ± 324183 ± 442071 ± 1004269 ± 523812 ± 67
SecondaryNab-P Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)

The nab-P area under the plasma concentration-time curve from time 0 extrapolated to infinite time (AUCinf) on Day -1 and Day 13 observed directly from data.

Time frame:
Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Reported as:
Geometric mean · ng.hr/mL
Nab-P Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)
ng.hr/mLDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Day -1NA ± NA3851 ± 503780 ± 304157 ± 485387 ± 545132 ± 564116 ± 344760 ± 494977 ± 46
Day 13NA ± NANA ± NA4590 ± 603349 ± 674493 ± 294482 ± 462206 ± 1185135 ± 384447 ± 55
SecondaryNab-P Terminal Plasma Elimination Half-life (t1/2)

The nab-P t1/2 on Day -1 and Day 13 were observed directly from data.

Time frame:
Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Reported as:
Median · hr
Nab-P Terminal Plasma Elimination Half-life (t1/2)
hrDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Day -116.95 (16.6 to 17.3)11.10 (7.75 to 18.6)12.00 (10.9 to 16.6)15.25 (10.0 to 20.1)12.85 (9.41 to 16.1)16.10 (9.30 to 31.3)15.80 (9.31 to 20.4)14.45 (8.86 to 20.8)14.50 (7.75 to 31.3)
Day 1315.20 (13.4 to 17.0)17.65 (13.0 to 22.3)18.60 (12.3 to 20.8)16.40 (15.7 to 19.3)17.10 (7.51 to 21.9)13.80 (9.82 to 18.8)14.35 (2.76 to 18.8)14.40 (9.26 to 24.3)15.20 (2.76 to 24.3)
SecondaryNab-P Clearance (CL)

The nab-P clearance on Day -1 and Day 13 were observed directly from data.

Time frame:
Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Reported as:
Geometric mean · liter per hour (L/hr)
Nab-P Clearance (CL)
liter per hour (L/hr)DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Day -1NA ± NA42.05 ± 5660.94 ± 3641.69 ± 5137.77 ± 4644.02 ± 5142.39 ± 3447.39 ± 4843.63 ± 46
Day 13NA ± NANA ± NA52.34 ± 6550.14 ± 7846.37 ± 3347.89 ± 4876.34 ± 13144.92 ± 4049.35 ± 57
SecondaryNab-P Volume of Distribution (Vz)

The nab-P on Day -1 and Day 13 were observed directly from data.

Time frame:
Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Reported as:
Geometric mean · L
Nab-P Volume of Distribution (Vz)
LDL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Overall Participants With Dose Normalized to 125 mg/m^2.
Day -1NA ± NA709.1 ± 441140 ± 44891.3 ± 37701.6 ± 46943.3 ± 56904.5 ± 39950.8 ± 51873.3 ± 46
Day 13NA ± NANA ± NA1271 ± 1061235 ± 691070 ± 71927.2 ± 321220 ± 57971.1 ± 521036 ± 52

Adverse events

Collected over From the signing of informed consent up to 56 days after the last administration of the investigational product, or 365 days from the first dose of investigational product, whichever is later.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DL1 Palbociclib 75mg / Nab-Paclitaxel 100mg/m^20/3 (0%)2/3 (66.7%)3/3 (100%)
DL2A Palbociclib 100mg / Nab-Paclitaxel 100mg/m^21/7 (14.3%)4/7 (57.1%)7/7 (100%)
DL2B Palbociclib 75mg / Nab-Paclitaxel 125mg/m^23/4 (75%)3/4 (75%)4/4 (100%)
DL3A Palbociclib 125mg / Nab-Paclitaxel 100mg/m^22/11 (18.2%)4/11 (36.4%)11/11 (100%)
DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^23/11 (27.3%)6/11 (54.5%)10/11 (90.9%)
MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^25/11 (45.5%)9/11 (81.8%)11/11 (100%)
MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^22/9 (22.2%)2/9 (22.2%)9/9 (100%)
MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^26/20 (30%)12/20 (60%)20/20 (100%)
MTD+DL3B7/27 (25.9%)15/27 (55.6%)27/27 (100%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventDL1 Palbociclib 75mg / Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg / Nab-Paclitaxel 100mg/m^2DL2B Palbociclib 75mg / Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg / Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
Disease progressionGeneral disorders0/31/71/40/111/114/110/91/202/27
Abdominal painGastrointestinal disorders1/30/70/40/110/111/110/92/202/27
vomitingGastrointestinal disorders1/30/70/40/110/111/110/91/201/27
Liver abscessInfections and infestations1/30/70/40/110/111/110/90/200/27
EmpyemaInfections and infestations1/30/70/40/110/110/110/90/200/27
Pleural effusionRespiratory, thoracic and mediastinal disorders1/30/70/40/110/111/110/90/200/27
CholangitisHepatobiliary disorders0/32/71/40/110/111/110/90/200/27
PyrexiaGeneral disorders0/30/71/41/110/110/110/90/200/27
Back painMusculoskeletal and connective tissue disorders0/30/71/40/110/110/110/90/200/27
SeizureNervous system disorders0/30/71/40/110/110/110/90/200/27
Most frequent other events
Showing 10 of 172
Most frequent other events
EventDL1 Palbociclib 75mg / Nab-Paclitaxel 100mg/m^2DL2A Palbociclib 100mg / Nab-Paclitaxel 100mg/m^2DL2B Palbociclib 75mg / Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg / Nab-Paclitaxel 100mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MTD+DL3B
DiarrhoeaGastrointestinal disorders1/36/71/42/114/115/112/99/2012/27
AlopeciaSkin and subcutaneous tissue disorders1/36/71/43/114/116/113/96/209/27
NeutropeniaBlood and lymphatic system disorders2/35/71/49/117/115/116/916/2020/27
Early satietyGeneral disorders2/31/70/40/110/110/110/90/200/27
PyrexiaGeneral disorders2/34/71/40/111/112/111/95/206/27
DehydrationMetabolism and nutrition disorders2/30/71/40/112/111/110/93/205/27
DysgeusiaNervous system disorders2/33/71/40/111/111/111/90/201/27
Decreased appetiteMetabolism and nutrition disorders1/32/71/41/114/117/115/93/207/27
Abdominal painGastrointestinal disorders1/33/70/41/112/114/115/94/205/27
AnaemiaBlood and lymphatic system disorders1/32/72/45/113/116/111/99/2011/27

Baseline characteristics

The baseline analysis population included all participants enrolled in the study.

Age, Customized
Age, Customized(Participants)DL1 Palbociclib 75 mg/Nab-Paclitaxel 100 mg /m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100mg/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100 mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Total
<18000000000
18-44010100024
45-642535678945
65-751115541927
>75000000000
Sex: Female, Male
Sex: Female, Male(Participants)DL1 Palbociclib 75 mg/Nab-Paclitaxel 100 mg /m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100mg/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100 mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Total
Female2516536634
Male12356831442
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DL1 Palbociclib 75 mg/Nab-Paclitaxel 100 mg /m^2DL2A Palbociclib 100mg/Nab-Paclitaxel 100mg/m^2DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2DL3A Palbociclib 125mg/Nab-Paclitaxel 100 mg/m^2DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2Total
White36411111182074
Asian010000102
08

Study locations

26 sites
  • Scottsdale Healthcare Hospitals DBA HonorHealth
    Scottsdale, Arizona 85258, United States
  • Virginia G. Piper Cancer Pharmacy
    Scottsdale, Arizona 85258, United States
  • UC San Diego Medical Center - La Jolla (Thornton Hospital)
    La Jolla, California 92037-0845, United States
  • UC San Diego Moores Cancer Center - Investigational Drug Services
    La Jolla, California 92037-0845, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • UC San Diego Medical Center - Hillcrest
    San Diego, California 92103, United States
  • Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • University of Colorado Denver, CTO (CTRC)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
    Aurora, Colorado 80045, United States
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231-1000, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Siteman Cancer Center - West County
    Creve Coeur, Missouri 63141, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Washington University Infusion Center Pharmacy
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Siteman Cancer Center - South County
    Saint Louis, Missouri 63129, United States
  • Siteman Cancer Center
    Saint Peters, Missouri 63376, United States
  • University of Utah, Huntsman Cancer Hospital
    Salt Lake City, Utah 84112, United States
  • University of Utah, Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Hospital Universitario de Fuenlabrada. Unidad de Farmacia
    Fuenlabrada, Madrid 28942, Spain
  • Hospital Universitario Fuenlabrada
    Fuenlabrada, Madrid 28942, Spain
  • Hospital Universitari Vall D'Hebron, Servicio de Oncología Médica
    Barcelona, 08035, Spain
  • Hospital Universitario 12 de Octubre Servicio de Farmacia
    Madrid, 28041, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Oct 2018, 34 months.

Results were first posted in Apr 2021, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2015
First posted
Jul 17, 2015
StartActual
Nov 23, 2015
Primary completionActual
Oct 10, 2018
CompletionActual
Dec 27, 2018
Results first posted
Apr 6, 2021
Last update
Apr 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02501902
Lead sponsor
Pfizer
Collaborators
Celgene
Responsible party
Sponsor
First posted
Jul 17, 2015
Start date
Nov 23, 2015
Primary completion
Oct 10, 2018
Completion
Dec 27, 2018
Results posted
Apr 6, 2021
Last update
Apr 6, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Palbociclib · Albumin-Bound Paclitaxel

Start the discussion